{
    "nctId": "NCT06169072",
    "briefTitle": "Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients",
    "officialTitle": "Sentinel Lymph Node Localisation With an Ultra-low Dose of Superparamagnetic Iron Oxide Nanoparticles in Patients With Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Sentinel Lymph Node",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 220,
    "primaryOutcomeMeasure": "SLN detection rate for Magtrace 0.1 ml and for dual technique (Tc99 +/- blue dye) measured as per cent of patients where a SLN is identified using either the magnetic or the dual technique.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Planned for sentinel lymph node biopsy at (or after) breast surgery\n* Signed and dated written informed consent before the start of specific protocol procedures\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding\n* Iron overload disease\n* Known hypersensitivity to iron, dextran compounds or blue dye.\n* Inability to understand given information and give informed consent or undergo study procedures",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}